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Group W invasive meningococcal disease (MenW IMD) has steadily increased in England 1 
since 2009.1, 2 This increase has occurred in all regions and age groups, and is due to the rapid 2 
expansion of a single endemic hyper-virulent strain belonging to the sequence type 11 clonal 3 
complex (ST-11cc). MenW ST-11cc IMD is associated with more severe and atypical 4 
presentations compared to group B disease.1 In response, the Joint Committee on Vaccination 5 
and Immunisation (JCVI) recommended the introduction of meningococcal ACWY 6 
(MenACWY) conjugate vaccine to the national immunisation programme in England.1, 3 7 
Public Health England (PHE) initiated this programme on the 26th June 2015. As a result, 8 
MenACWY vaccine replaced the existing time-limited ‘freshers’ programme from August 9 
2015, and was substituted directly for MenC vaccine in the routine adolescent school 10 
programme for 14-15 year olds. Currently, a catch-up campaign is also being implemented to 11 
offer MenACWY vaccine to all 14-18 year olds.3, 4  12 
The rationale for targeting the vaccine solely at older adolescent and young adults is that this 13 
group represents the main reservoir of meningococcal carriage.5 Introduction of the MenC 14 
conjugate vaccine previously reduced carriage of MenC strains in this population6, 7 and 15 
evidence suggests that the quadrivalent vaccine may have a similar effect on carriage of 16 
MenW strains.8 Reduced carriage in this population should lead to other age groups being 17 
protected indirectly.9  18 
In this study, we report MenACWY vaccine coverage in first year students arriving at the 19 
University of Nottingham (UoN) in September 2015. We also report the uptake of 20 
MenACWY vaccine offered to unvaccinated students via a campus-based mass vaccination 21 
campaign as part of a local initiative by the University of Nottingham Health Service 22 
(UNHS), in liaison with UoN, during the registration period.  23 
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Following approval by the Research Ethics Committee at the UoN, students were recruited to 24 
assess the uptake of MenACWY conjugate vaccination prior to arrival at the university. 25 
During registration (17-23rd September 2015), as part of standard clinical practice, 26 
interviews were conducted with each student by UNHS healthcare professionals and their 27 
vaccination history was confirmed and recorded on the UNHS registration database. Students 28 
who reported that they had not received MenACWY vaccine during the interview were 29 
offered immediate pro gratis vaccination with Menveo. Searches of the UNHS registration 30 
database (EMIS Web software; EMIS Health, Leeds, UK software) were later performed to 31 
determine vaccine coverage in the registered first year student population prior to arrival at 32 
the UoN and in a subgroup of international students. Uptake of MenACWY vaccine during 33 
registration was also assessed by UNHS database search and separately, to provide 34 
corroborative data, by a self-reported questionnaire from 134 students recruited post-35 
registration on 28th and 29th September 2015 in two separate halls of residence on the main 36 
campus of the UoN.  37 
During the registration period, 7049 first year students (aged 17-25 years) registered with the 38 
UNHS. On searching the UNHS database, 2160 (31%) of the 7049 registered students were 39 
recorded as having received MenACWY conjugate vaccine prior to arrival at the UoN. Of the 40 
remaining 4889 students who were eligible for vaccination, 2809 (57%) accepted the offer of 41 
vaccination and 2080 (43%) declined vaccination. Overall, following registration, 42 
MenACWY vaccine coverage in first year students at the UoN as assessed by UNHS 43 
database search increased from 31% to 71%. From the follow-up questionnaire post-44 
registration on 28th and 29th September 2015, MenACWY vaccine coverage in 134 students 45 
was found to be 64% confirming the significant rise in coverage following the UNHS 46 
campaign. Students’ self-reported vaccination status agreed with that in their health record. 47 
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In a subset of 804 international students aged 17-25 years, who registered with UNHS on 17th 48 
and 18th September 2015, only 7 (1%) confirmed they had already received the MenACWY 49 
vaccine prior to arrival. Of the remaining 797, 572 (72%) accepted and 225 (28%) declined 50 
vaccination. International students, compared to UK-based students, are less likely to have 51 
received MenACWY vaccine in their home country prior to arriving at university in UK.  52 
Nevertheless, uptake of MenACWY vaccine when offered was equally as good in this group.  53 
In the absence of a local mass vaccination campaign, it is likely that coverage would be 54 
particularly low in international students, placing them at risk of MenW disease. 55 
The overall vaccine coverage of 31% in this population of first year students on arrival at the 56 
UoN is unsurprisingly low but did confirm that the national vaccination campaign was 57 
successful in reaching a proportion of prospective English university students. PHE have 58 
used a temporary general practice-based sentinel surveillance system to provide a provisional 59 
estimate of vaccination coverage for the first cohort offered MenACWY vaccine from August 60 
2015. An evaluation at the end of January 2016 suggested that coverage was 33.7%10, which 61 
is consistent with our findings. The slightly lower MenACWY vaccine coverage found in our 62 
student population is likely to be due to the inclusion of a proportion of international students 63 
who were much less likely to have received vaccination before arrival.  64 
High rates of transmission of meningococcal strains occur in students during the first year of 65 
university attendance. As students also exhibit high mobility and wide geographical 66 
distribution, they represent a major vehicle for spread of meningococcal strains into 67 
communities throughout the UK. Targeting of this age group with the MenACWY vaccine 68 
has the potential to significantly perturb spread of the virulent MenW ST-11cc strain. If 69 
representative of coverage in this age group as a whole in England, ca. 30% MenACWY 70 
vaccine coverage may be too low to significantly reduce meningococcal carriage and 71 
transmission, accepting that the level of coverage needed to achieve such an effect is not 72 
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known. Consequently, a herd protection effect leading to a fall in MenW IMD may not be 73 
achieved in the short term. In contrast, the significant boost in coverage (from 31% to 71%) 74 
following the vaccine campaign at registration at the UoN demonstrates the importance of 75 
offering vaccination at enrolment in tertiary educational establishments and suggests that a 76 
more general implementation of this strategy may significantly improve vaccine coverage in 77 
this age group. As the cost of the MenACWY vaccine is funded centrally for first year 78 
university students as part of the national campaign, and an administration fee is also 79 
provided (currently £9.80 per vaccine administered), the campus-based mass vaccination 80 
campaign was essentially cost-neutral as advertising and the necessary facilities were 81 
arranged and provided in liaison with the host institution as part of the pastoral care for new 82 
students. The campus-based mass vaccination campaign delivered during the registration 83 
period, also provided significant logistical advantages compared with offering a large number 84 
of individual appointments for students to receive vaccination. However, a substantial 85 
proportion of unvaccinated students still declined vaccination (due to a lack of perceived 86 
need or benefit) suggesting that further advertising of the national campaign will be necessary 87 
to raise awareness and acceptance of the MenACWY vaccine in this demographic. 88 
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